Literature DB >> 18646001

Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma.

Takahiro Uenishi1, Shuhei Nishiguchi, Shogo Tanaka, Takatsugu Yamamoto, Shigekazu Takemura, Shoji Kubo.   

Abstract

BACKGROUND: Interferon therapy might reduce recurrence after resection of hepatitis C virus-related hepatocellular carcinoma, especially among sustained virologic or biochemical responders.
METHODS: Of 209 patients who underwent curative resection for early-stage hepatitis C virus related hepatocellular carcinoma, 70 patients underwent interferon therapy. A sustained virologic or biochemical response was achieved in 40 patients (SVR/BR group). Thirty no responders and 139 patients who had not received interferon therapy were classified as the NR/non-IFN group. Risk factors for postoperative recurrence in each group were analyzed.
RESULTS: The tumor-free survival rates in the SVR/BR group were significantly higher than those in the NR/non-IFN group. By multivariate analysis, the presence of multiple tumors was independently associated with recurrence after resection in both groups, while histologic evidence of cirrhosis was another independent risk factor for postoperative recurrence in the NR/non-IFN group.
CONCLUSIONS: Newly multicentric carcinogenesis after resection could be suppressed when active hepatitis is controlled by interferon therapy. Patients with single hepatitis C virus related hepatocellular carcinoma detected after successful interferon therapy are good candidates for surgical resection. Adjuvant interferon therapy might be indicated for patients who undergo curative resection for single hepatocellular carcinoma associated with hepatitis C. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 18646001     DOI: 10.1002/jso.21111

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  8 in total

1.  Surgical outcomes and clinical characteristics of elderly patients undergoing curative hepatectomy for hepatocellular carcinoma.

Authors:  Fumitoshi Hirokawa; Michihiro Hayashi; Yoshiharu Miyamoto; Mitsuhiro Asakuma; Tetsunosuke Shimizu; Koji Komeda; Yoshihiro Inoue; Atsushi Takeshita; Yuro Shibayama; Kazuhisa Uchiyama
Journal:  J Gastrointest Surg       Date:  2013-09-04       Impact factor: 3.452

2.  Prevention of cancer recurrence after treatment for hepatitis C virus-related hepatocellular carcinoma by interferon therapy.

Authors:  Shoji Kubo
Journal:  Clin J Gastroenterol       Date:  2009-04-08

Review 3.  Viral hepatitis and hepatocellular carcinoma: etiology and management.

Authors:  Philippe J Zamor; Andrew S deLemos; Mark W Russo
Journal:  J Gastrointest Oncol       Date:  2017-04

Review 4.  Adjuvant therapy after curative resection for hepatocellular carcinoma associated with hepatitis virus.

Authors:  Shoji Kubo; Shigekazu Takemura; Chikaharu Sakata; Yorihisa Urata; Takahiro Uenishi
Journal:  Liver Cancer       Date:  2013-01       Impact factor: 11.740

5.  Long-Term Prognostic Factors after Hepatic Resection for Hepatitis C Virus-Related Hepatocellular Carcinoma, with a Special Reference to Viral Status.

Authors:  Masaki Koda; Shogo Tanaka; Shigekazu Takemura; Hiroji Shinkawa; Masahiko Kinoshita; Genya Hamano; Tokuji Ito; Norifumi Kawada; Toshihiko Shibata; Shoji Kubo
Journal:  Liver Cancer       Date:  2018-03-13       Impact factor: 11.740

6.  Long-term effects of antiviral therapy in patients with chronic hepatitis C.

Authors:  Tatehiro Kagawa; Emmet B Keeffe
Journal:  Hepat Res Treat       Date:  2010-09-27

Review 7.  Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits.

Authors:  Jayne Smith-Palmer; Karin Cerri; William Valentine
Journal:  BMC Infect Dis       Date:  2015-01-17       Impact factor: 3.090

8.  Development of a miR-26 companion diagnostic test for adjuvant interferon-alpha therapy in hepatocellular carcinoma.

Authors:  Junfang Ji; Lei Yu; Zhipeng Yu; Marshonna Forgues; Takahiro Uenishi; Shoji Kubo; Kenichi Wakasa; Jian Zhou; Jia Fan; Zhao-You Tang; Shijun Fu; Hongguang Zhu; Jason Gang Jin; Hui-Chuan Sun; Xin Wei Wang
Journal:  Int J Biol Sci       Date:  2013-03-16       Impact factor: 6.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.